Is GSK3β a molecular target of chloroquine treatment against COVID-19?
Autor: | Mohammed Noor Embi, Nagesswary Ganesan, Hasidah Mohd Sidek |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Drug Melioidosis media_common.quotation_subject Pneumonia Viral Anti-Inflammatory Agents Pharmacology Betacoronavirus 03 medical and health sciences 0302 clinical medicine Chloroquine Animals Medicine Pharmacology (medical) Phosphorylation General Pharmacology Toxicology and Pharmaceutics Protein kinase A Glycogen synthase Pandemics media_common Glycogen Synthase Kinase 3 beta biology SARS-CoV-2 business.industry Burkholderia pseudomallei COVID-19 Hydroxychloroquine General Medicine medicine.disease biology.organism_classification COVID-19 Drug Treatment Disease Models Animal 030104 developmental biology 030220 oncology & carcinogenesis biology.protein Coronavirus Infections business medicine.drug |
Zdroj: | Drug Discoveries & Therapeutics. 14:107-108 |
ISSN: | 1881-784X 1881-7831 |
DOI: | 10.5582/ddt.2020.03010 |
Popis: | The recent clinical trial reports pertaining to the efficacy of chloroquine and hydroxychloroquine against COVID-19 albeit yet to be validated with larger clinical trials, have sparked much interest globally to evaluate whether this anti-malarial drug can be repurposed for the treatment of COVID-19. In addition to its anti-viral activity, the anti-inflammatory activity of chloroquine may also contribute to its efficacy. Based on our data obtained from an animal infection model of melioidosis (a disease caused by the bacteria Burkholderia pseudomallei), treatment with chloroquine can result in the phosphorylation and consequent inhibition of glycogen synthase kinase-3β (GSK3β). This serine/threonine protein kinase is now recognised as a point of convergence for host inflammatory response. In view of this, it is plausible that the mechanism for the anti-inflammatory effect of chloroquine against COVID-19 involves inhibition of host GSK3β. |
Databáze: | OpenAIRE |
Externí odkaz: |